Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel versus surveillance after radical prostatectomy in high‑risk prostate cancer
2005-002355-40Phase 3Active
- Sponsor
- Scandinavian Prostate Cancer Group
- Start
- Jun 2005
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel in prostate cancer (PCa) (2 arms), sponsored by Scandinavian Prostate Cancer Group. Primary endpoint: PSA progression. Started Jun 2005; status: active.
02
Drugs
docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2005-002355-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002355-40.